Glioblastoma multiforme

被引：4

作者：

Welch, Mary ^{[1
]}

Lai, Rose ^{[1
]}

机构：

[1] Columbia Univ, Neurol Inst, New York, NY 10032 USA

来源：

CURRENT TREATMENT OPTIONS IN NEUROLOGY | 2009年 / 11卷 / 04期

基金：

英国医学研究理事会;

关键词：

PHASE-II TRIAL; NEWLY-DIAGNOSED GLIOBLASTOMA; GROWTH-FACTOR RECEPTOR; RECURRENT GLIOBLASTOMA; RADIATION-THERAPY; MALIGNANT GLIOMA; TEMOZOLOMIDE; RADIOTHERAPY; OUTCOMES; BEVACIZUMAB;

D O I：

10.1007/s11940-009-0033-5

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Optimal management of newly diagnosed glioblastoma multiforme includes maximal surgical resection, followed by 60 Gy of external beam radiation plus concomitant daily temozolomide and at least six additional monthly cycles of maintenance temozolomide. Several large phase 3 trials are now ongoing to determine whether agents added to this regimen may confer further survival advantage. At the time of disease recurrence, bevacizumab is the most commonly used agent. Whenever feasible, patients should be encouraged to participate in clinical trials, which are currently focused on antiangiogenic and targeted therapies.

引用

页码：297 / 305

页数：9

共 49 条

[1] Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma [J].

Barnholtz-Sloan, Jill S. ;

Williams, Vonetta L. ;

Maldonado, John L. ;

Shahani, Dilip ;

Stockwell, Heather G. ;

Chamberlain, Marc ;

Sloan, Andrew E. .

JOURNAL OF NEUROSURGERY, 2008, 108 (04) :642-648

[2] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].

Batchelor, Tracy T. ;

Sorensen, A. Gregory ;

di Tomaso, Emmanuelle ;

Zhang, Wei-Ting ;

Duda, Dan G. ;

Cohen, Kenneth S. ;

Kozak, Kevin R. ;

Cahill, Daniel P. ;

Chen, Poe-Jou ;

Zhu, Mingwang ;

Ancukiewicz, Marek ;

Mrugala, Maciej M. ;

Plotkin, Scott ;

Drappatz, Jan ;

Louis, David N. ;

Ivy, Percy ;

Scadden, David T. ;

Benner, Thomas ;

Loeffler, Jay S. ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

CANCER CELL, 2007, 11 (01) :83-95

[3] Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma:: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) [J].

Brandes, A. A. ;

Tosoni, A. ;

Cavallo, G. ;

Bertorelle, R. ;

Gioia, V. ;

Franceschi, E. ;

Biscuola, M. ;

Blatt, V. ;

Crino, L. ;

Ermani, M. .

BRITISH JOURNAL OF CANCER, 2006, 95 (09) :1155-1160

[4] MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients [J].

Brandes, Alba A. ;

Franceschi, Enrico ;

Tosoni, Alicia ;

Blatt, Valeria ;

Pession, Annalisa ;

Tallini, Giovanni ;

Bertorelle, Roberta ;

Bartolini, Stefania ;

Calbucci, Fabio ;

Andreoli, Alvaro ;

Frezza, Giampiero ;

Leonardi, Marco ;

Spagnolli, Federica ;

Ermani, Mario .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2192-2197

[5] Epidermal growth factor receptor inhibitors in neuro-oncology: Hopes and disappointments [J].

Brandes, Alba A. ;

Franceschi, Enrico ;

Tosoni, Alicia ;

Hegi, Monika E. ;

Stupp, Roger .

CLINICAL CANCER RESEARCH, 2008, 14 (04) :957-960

[6] PLACEBO-CONTROLLED TRIAL OF SAFETY AND EFFICACY OF INTRAOPERATIVE CONTROLLED DELIVERY BY BIODEGRADABLE POLYMERS OF CHEMOTHERAPY FOR RECURRENT GLIOMAS [J].

BREM, H ;

PIANTADOSI, S ;

BURGER, PC ;

WALKER, M ;

SELKER, R ;

VICK, NA ;

BLACK, K ;

SISTI, M ;

BREM, S ;

MOHR, G ;

MULLER, P ;

MORAWETZ, R ;

SCHOLD, SC .

LANCET, 1995, 345 (8956) :1008-1012

[7] A phase II trial of sunitinib in patients with recurrent high-grade glioma [J].

Chaskis, C. ;

Sadones, J. ;

Michotte, A. ;

Dujardin, M. ;

Everaert, H. ;

Neyns, B. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[8] Comprehensive genomic characterization defines human glioblastoma genes and core pathways [J].

Chin, L. ;

Meyerson, M. ;

Aldape, K. ;

Bigner, D. ;

Mikkelsen, T. ;

VandenBerg, S. ;

Kahn, A. ;

Penny, R. ;

Ferguson, M. L. ;

Gerhard, D. S. ;

Getz, G. ;

Brennan, C. ;

Taylor, B. S. ;

Winckler, W. ;

Park, P. ;

Ladanyi, M. ;

Hoadley, K. A. ;

Verhaak, R. G. W. ;

Hayes, D. N. ;

Spellman, Paul T. ;

Absher, D. ;

Weir, B. A. ;

Ding, L. ;

Wheeler, D. ;

Lawrence, M. S. ;

Cibulskis, K. ;

Mardis, E. ;

Zhang, Jinghui ;

Wilson, R. K. ;

Donehower, L. ;

Wheeler, D. A. ;

Purdom, E. ;

Wallis, J. ;

Laird, P. W. ;

Herman, J. G. ;

Schuebel, K. E. ;

Weisenberger, D. J. ;

Baylin, S. B. ;

Schultz, N. ;

Yao, Jun ;

Wiedemeyer, R. ;

Weinstein, J. ;

Sander, C. ;

Gibbs, R. A. ;

Gray, J. ;

Kucherlapati, R. ;

Lander, E. S. ;

Myers, R. M. ;

Perou, C. M. ;

McLendon, Roger .

NATURE, 2008, 455 (7216) :1061-1068

[9] Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations [J].

Chinot, OL ;

Barrie, M ;

Frauger, E ;

Dufour, H ;

Figarella-Branger, D ;

Palmari, J ;

Braguer, D ;

Hoang-Xuan, K ;

Moktari, K ;

Peragut, JCC ;

Martin, PMM ;

Grisoli, F .

CANCER, 2004, 100 (10) :2208-2214

[10] A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) [J].

Cloughesy, T. F. ;

Prados, M. D. ;

Wen, P. Y. ;

Mikkelsen, T. ;

Abrey, L. E. ;

Schiff, D. ;

Yung, W. K. ;

Maoxia, Z. ;

Dimery, I. ;

Friedman, H. S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →